BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced on Monday that its pivotal Phase 3 Bria-ABC study has screened more than 315 patients and enrolled over 230 patients in its evaluation of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer. Notably, the company anticipates reporting interim topline data in 2026.
Strong Enrollment Momentum
The clinical-stage biotechnology company, which develops novel immunotherapies aimed at transforming cancer care, continues to attract increased interest from leading cancer centers. Furthermore, enrollment momentum has accelerated following the independent inclusion of its Phase 3 clinical trial in Nature Medicine’s article, “Eleven clinical trials that will shape medicine in 2026.”
Currently, the Phase 3 Bria-ABC study is evaluating BriaCell’s lead clinical candidate, Bria-IMT, in combination with an immune checkpoint inhibitor versus physician’s choice of treatment in advanced breast cancer.
Interim Analysis on the Horizon
Importantly, BriaCell will conduct the interim analysis after 144 patient events, defined as deaths, have occurred. Overall survival (OS) serves as the primary endpoint, and positive results could support full approval of Bria-IMT in patients with metastatic breast cancer. In addition, the Bria-IMT combination regimen has already received FDA Fast Track designation.
Leadership Commentary
“Sustained and new interest from world class institutions and their patients continues to drive remarkable patient engagement,” stated Dr. William V. Williams, BriaCell’s President & CEO. He added, “We remain on track to report the interim analysis in 2026 while continuing to enroll patients and advance preparations for potential commercialization, with the goal of bringing our novel immunotherapy regimen to patients with metastatic breast cancer as efficiently as possible.”
About the Study
For additional information on BriaCell’s pivotal Phase 3 study, investors can visit ClinicalTrials.gov under identifier NCT06072612.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. For more investor relations information please visit www.investors briacell.com.
